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Abstract
Background: Heart failure (HF) is mainly detected and managed in primary care, but the care is considered
suboptimal. We present the rationale, design and baseline results of the Treatment Optimisation in Primary care
of Heart failure in the Utrecht region (TOPHU) study. In this study we assess the effect of a single training of GPs in
the pharmacological management of patients with HF.
Methods/design: A cluster randomised controlled trial. Thirty primary care practices are randomly assigned to care
as usual or intervention defined as a single training in the up-titration and management of HF drug therapy
according to the heart failure guidelines of the European Society of Cardiology (ESC). Patients with a GP’s diagnosis
of HF will be re-evaluated by an expert panel of two cardiologists and a GP with expertise in HF to come to a
definite diagnosis of HF according to the ESC heart failure guidelines. Those with definite HF will be analysed in this
study. Drug use will be measured after six months, health status after twelve months, and heart-related hospital
admissions and all-cause mortality after two years.
Discussion: Our cluster randomised trial will show whether a single training of GPs improves the pharmacological
management of patients with HF and confers beneficial effects on health status after one year, and cardiac hospital
admissions and all-cause mortality after two years of follow-up.
Trial registration: ClinicalTrials.gov Identifier NCT01662323
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Background
Heart failure (HF) is an important medical and health
care problem with great impact on patient’s health status
and life expectancy. The initial diagnosis of HF is mainly
made in primary care, and is still often based on the
clinical assessment only, irrespective of the general
knowledge that such a diagnosis solely based on clinical
grounds, without echocardiography bares the risk of
both overdiagnosis and underdiagnosis, certainly in the
early stages of slow-onset HF [1–4]. This knowledge is
also important because a previous study in primary care
suggested that uncertainty regarding the diagnosis of
heart failure is an important barrier to adequate drug
treatment by GPs [5]. Moreover, echocardiography is
needed to differentiate HF with a preserved ejection
fraction (HFpEF) from HF with a reduced ejection frac-
tion (HFrEF) [1]. Although, both types are part of the
heart failure spectrum, the treatment is different. In
HFpEF it is focussed on i) release of symptoms with di-
uretics in case of fluid retention, ii) adequate blood pres-
sure control, and iii) management of comorbidities.
Importantly, however, none of these treatments has a
clear prognostic benefit and thus lacks a real evidence-
* Correspondence: M.J.M.Valk-7@umcutrecht.nl
1Julius Center for Health Sciences and Primary Care, University Medical
Center Utrecht, Stratenum 6.131, PO Box 85500, 3508 AB Utrecht, The
Netherlands
Full list of author information is available at the end of the article
© 2015 Valk et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Valk et al. BMC Family Practice  (2015) 16:130 
DOI 10.1186/s12875-015-0347-1
base. On the other hand, for HFrEF there are multiple
drugs including angiotensin converting enzyme inhibi-
tors (ACE-i) or angiotensin receptor blockers (ARB), β-
blockers, and mineralocorticoid receptor antagonists
(MRA), and devices that reduce mortality and heart fail-
ure hospitalization as it does improve quality of life [1].
Ivabradine should be considered in the subgroup of pa-
tients who remain symptomatic with the three afore-
mentioned drugs, and have sinus rhythm with a pulse
frequency higher than 70 beats/min in rest [1].
Previous studies showed that general practitioners
(GPs) are less successful than cardiologists in up-
titrating HF drugs according to guidelines [2, 3, 6–9].
Nevertheless, they adequately maintain the drug man-
agement initiated in secondary care, as good as done in
heart failure clinics [10, 11].
We aim to determine whether a single training of GPs
focused on the drug management improves the pharma-
cological management of patients with definite HF,
HFrEF and HFpEF seperately. Additionally, we deter-
mine if it has a beneficial effect on health status, cardiac
hospital admissions, and all-cause mortality.
Key objectives
– To assess how many patients labelled with HF in
primary care really have heart failure.
– To assess the effect of a single half-day training on
drug management in heart failure on drug use,
health related quality of life, heart failure hospitaliza-
tions, and all-cause mortality after six months,
12 months, and 24 months, respectively.
Methods
Study design
We designed a cluster randomised trial with randomisa-
tion at the level of the primary care practices, to help
prevent contamination with the intervention. Thirty
practices are randomly divided into two groups of fif-
teen. The intervention group will receive a half-day
training on HF management and will receive an up-
titration chart for daily use in the management of HF
patients during the study, while the control group will
not receive specific training, and provides care as usual.
The study starts with the training, and participants in
both groups will be followed up for two years. After six
months of follow-up the electronic medical files will be
scrutinized for (change in) prescriptions of drugs in
comparison to baseline. Twelve months after the train-
ing the participants will be sent a questionnaire on
health status. After two years, hospital admissions and
all-cause mortality will be assessed, by again scrutinizing
the GPs’ electronical files (Fig. 1).
Recruitment of general practitioners
General practitioners (GPs) will be recruited in and around
Amersfoort, a city in the centre of the Netherlands. A rep-
resentative group of 195 GPs working in group, duo or solo
practices in urban, suburban, and rural areas were invited
by letter. Forty-five GPs working in 30 GP practices con-
sented to participate. They are all familiar with the Dutch
GP guideline on heart failure [12]. The participating general
practices were randomly allocated to either the intervention
or care as usual group. The project manager undertook
randomisation in a blinded fashion. GPs working in one
practice were allocated to the same group, to avoid contam-
ination of GPs and participants between the two groups,
which can occur if randomization is performed at an indi-
vidual participant level.
Study population and recruitment
All citizens in the Netherlands are registered with a GP,
also those who receive cooperative care from a medical
specialist, except those living in a nursing home or hos-
pice. All patients enlisted with the participating GPs and
who have a GP’s diagnosis of HF encoded according the
International Classification of Primary Care (ICPC) code
K77 will be assessed if this ICPC code was allocated at
least twice for patient contacts, to prevent single acci-
dental miscoding. Five months before the start of the
study, the electronic medical files of the 30 participating
GPs will be scrutinised for such patients labelled with
ICPC code K77, and if echocardiographic results are
missing, the GPs of both groups will be urged to consider
referral for echocardiography. The start of the study is the
date of training of the GPs in the intervention group. An
expert panel consisting of two cardiologists and an experi-
enced general practitioner will evaluate all available diag-
nostic information from the electronic medical files of the
GPs, including echocardiography results mentioned in
cardiologist’s papers when this investigation was per-
formed. They decide whom of those with ICPC code K77
has definite HF, probably or possibly HF, or no HF accord-
ing to the European Society of Cardiology guidelines [1].
Table 1 The diagnosis of heart failure according to the ESC
guidelines on heart failure 2012 [1]
Diagnosis of HF with a
reduced ejection fraction (HFrEF)
Diagnosis of HF with a preserved
ejection fraction (HFpEF)
Symptoms typical of HF Symptoms typical of HF
Signs typical of HFa Signs typical of HFa
Reduced left ventricular
ejection fraction
Normal or only mildly reduced left
ventricular ejection fraction and left
ventricle not dilated
Relevant structural heart disease
(LV hypertrophy/left atrial enlargement)
and/or diastolic dysfunction
HF heart failure
aSigns may not be present in the early stages of heart failure (especially in
HFpEF) and in patients treated with diuretics
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Only patients who have definite HF according to the panel
will be analysed in the cluster randomised trial. All partici-
pants will be asked to give written informed consent.
Sample size
We base our sample size calculation on the cases with
definite HFrEF. We speculate that 30 % of them will be
on a β-blocker and 60 % on an angiotensin converting
enzyme inhibitor (ACE-i) or angiotensin receptor
blocker (ARB) at baseline, and that after six months of
follow-up after the training session these percentages
will have increased to 60 and 90 %, respectively in the
intervention group, while remaining the same in the
control group. To prove a difference of 30 % in prescrip-
tion rates in ACE-i/ARBs and β-blockers between the
intervention and care as usual arm after six months with
an alpha of 0.05, a power of 0.80, and an intra-cluster
correlation coefficient of 0.05 [12], and a cluster size of
5, we need 47 patients with HFrEF in each study arm.
Considering a drop-out of 10 % we aim to include 52
participants in each arm (total 104). We calculated that
around 30 general practices should participate to recruit
104 patients with definite HFrEF.
Intervention and care as usual
GPs, GP trainees, and nurse practitioners of general
practices of the intervention arm receive a two hours
lasting interactive training on the diagnosis and pharma-
cological management of HF by a cardiologist and GP
with expertise in HF. Special attention will be paid to
initiation and up-titration to optimal dosage of
evidence-based drugs in patients with HFrEF, especially
in the drugs that should always be considered to be
prescribed; ACE-inhibitors or ARBs, beta-blockers, and
MRAs. The ‘hand-out’ leaflet to be used in everyday
practice will be explained (Fig. 2). This leaflet provides
detailed information on the intervals in the up-
titration, what should be checked at control visits,
contra-indications of the cardiovascular drugs, and la-
boratory tests needed (i.e., creatinine and potassium
levels). Differences in the drug management of patients
with HFrEF and HFpEF will be explained, as also the
most common interaction and adverse effects of HF
drugs. Finally, general aspects such as adherence, and
polypharmacy and options of self-care will be discussed
interactively. Participants of the training will not be re-
inforced by reminders, newsletters, or other communi-
cations after the training. GPs, GP trainees and practice
Fig. 1 Study scheme. ICPC = International Classification in Primary Care, PCP = primary care practice; HFrEF = heart failure with reduced ejection
fraction, HFpEF = heart failure with preserved ejection fraction, rs-HF = isolated right-sided heart failure. SF-36 and EQ-5D are health related quality
of live questionnaires. T0: start of the study with training of the GPs, GP trainees and practice nurses of the intervention group. T1: Six months of
follow-up; assessment of cardiovascular drug use in both groups in comparison to baseline. T2: Twelve months of follow-up; questionnaires on
health status (SF-36 and EQ-5D will be filled out by participants in both groups. T3: Two years of follow-up; assessment of hospitalisations and all-cause
mortality in the electronic medical files of the GPs in both groups
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Fig. 2 Up-titration scheme as provided on a leaflet to be used in everyday practice by the GPS in the intervention group
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nurses in the care as usual group will not receive such
a training nor an up-titration chart.
Panel procedure and the definite diagnosis of heart
failure
The expert panel will consist of two cardiologists and a
GP experienced in HF. They will decide during consen-
sus meetings on the presence or absence of HF following
the criteria of the HF guidelines of the ESC (Table 1). In
addition to symptoms and signs suggestive of HF add-
itional evidence from echocardiography of structural or
functional abnormality of the heart at rest is needed to
establish the presence of HF [1]. With the assumption
that all patients labelled with a GPs diagnosis of heart
failure have symptoms and signs suggestive of HF, the
panel will evaluate, when available, the results from add-
itional diagnostic testing such as natriuretic peptide
values, chest X-ray, electrocardiography and echocardi-
ography. Based on consensus, the panel decides if a pa-
tient has no HF, probably or possibly HF, or definite HF.
Only patients with definite HF according to the panel
will be analysed in the cluster randomized trial.
Cases with definite HF will further be subdivided in
HFrEF, HFpEF, and isolated right-sided HF (rs-HF). For
HFrEF, a reduced left ventricular ejection fraction
(LVEF) is needed, arbitrary ≤ 45 %. For HFpEF, the LVEF
should be normal or nearly normal, arbitrary >45 %, this
in the presence of at least two structural or functional
abnormalities related to relaxation such as a left atrium
volume indexed (LAVI) >34 ml/m2, E/e’ >15, E/A <0.75,
and/or a left ventricular wall thickness >11 mm. In those
with atrial fibrillation, a LAVI >34 ml/m2 is sufficient for
the diagnosis of diastolic dysfunction. For isolated right-
sided heart failure, the LVEF should be >45 %, and the
calculated peak pulmonary pressure >40 mmHg that is
insufficiently explained by left ventricular dysfunction.
Data collection
At baseline, the following data will be extracted from the
electronic medical files of the participants: age, gender,
cardiovascular drug use, comorbidities, the most recent
blood test results including natriuretic peptide measure-
ments (NTproBNP or BNP) and the eGFR, whether
echocardiography was performed, and if the patient re-
ceived cooperative care from a cardiologist. Such co-
operative care is considered present when a patient
consulted a cardiologist at least once in the 18 months
before the start of the study. Six months after the train-
ing, the prescription of cardiovascular drugs in both
arms will again be extracted from the GPs’ electronic
medical files. After one year, participants in both arms
will be asked to fill out two health status questionnaires
(the Short Form 36 and the five dimensional Euro Qual
(EQ-5D) [13, 14, 15]. Two years after the start of the
study, the GPs’ electronic medical files will be scruti-
nized again to assess hospital admissions and all-cause
mortality. See also Fig. 1.
Outcomes
Study outcomes are the proportions of patients labelled
with ICPC K77 who really have heart failure according
to the expert panel, and the proportion of patients with
definite heart failure and a reduced ejection fraction that
received the most relevant and universally needed HF
drugs, including ACE-i/ARBs, β-blockers, and min-
eralocorticoid receptor antagonists. Drug use at base-
line and after six months will be compared between
the two groups.
Health status will be assessed with the SF-36 and the EQ-
5D in all with definite HF (HFrEF and HFpEF). The SF-36
is subdivided into eight domains: physical functioning, so-
cial functioning, limitations in usual role activities due to
physical problems, limitations in usual role activities due to
emotional problems, bodily pain, general vitality health,
general mental health, general health perception. Scores
range from 0 to 100. The EQ-5D questionnaire has five di-
mensions: mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression, which are divided into three
degrees of severity; “no problem”, “some problems” or
“major problems”. A single index score can be produced
using information from these five dimensions. Higher
scores on both questionnaires are associated with a better
health-related quality of life.
Also cardiac and other hospitalisation will be
assessed in all with definite HF, and the duration of
hospitalisation.
Data analyses
We will calculate with its 95 % confidence interval how
many patients with an ICPC code K77 were correctly di-
agnosed with heart failure according to the expert panel.
The proportion of prescribed HF drugs between the two
groups will be compared after six months taking into ac-
count baseline differences. The difference in health status
between participants with definite HF in the two study
arms at 12 months will be compared with ANCOVA. Dif-
ferences between participants of the two groups regarding
hospitalisations and all-cause mortality will be assessed
after two years. A multilevel approach will be used in the
analyses to correct for the fact that we randomized at the
GP practice and not at the patient level.
Regulation statement
This study is conducted according to the principles of
the current version of the declaration of Helsinki and in
accordance with the Dutch law on Medical Research in-
volving Human Subjects Act (WMO).
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Ethics committee approval
The study was approved by the Regional Medical Ethics
Committee (VCMO) of the Meander Medical Centre,
Amersfoort, the Netherlands.
Discussion
In this study we will quantify how many patients with a
GP’s diagnosis of heart failure really have heart failure.
In a randomised trial we will quantify the effect on drug
use, health status and prognosis with hospital admis-
sions, and all-cause mortality of a single training of GP’s
that is focused on the drug management of patients with
definite HF, and for HFrEF and HFpEF seperately.
There are several limitations to be mentioned. First, a
two-hour training is short to adequately train GPs how
to initiate and up-titrate heart failure medication in pa-
tients with HFrEF, even if they are familiar with heart
failure guidelines, receive a helpful leaflet, and with over
half of the patients receiving cooperative care from the
cardiologist. For logistical and practical reasons we
choose for such a single intervention because it resem-
bles most closely post-graduate education GPs receive in
the Netherlands. Secondly, we measure outcomes only
once; drug prescriptions after 6 months, hr-QoL after
12 months, and CV morbidity and mortality after
24 months. More frequent measurements of outcomes
would result in ‘disturbing’ GPs, and multiple times fill-
ing out questionnaires by participants. It would easily re-
sult in ‘drifting away’ from ‘real’ care as usual of those in
that arm of the study. Thirdly, not all patients will
undergo echocardiography in this practice-based study.
The advantage of a practice study is the inclusion of
‘real’ patients and the assessment of drugs in ‘real’ prac-
tice. The downside is missings on some variables. In real
live practice not everybody labeled with heart failure
underwent echocardiography. Nevertheless, for our clus-
ter randomized trial we will selectively analyse those
with definite HF, that is, symptoms of HF and func-
tional/ structural abnormalities with echocardiography,
evaluated by an expert panel of two cardiologists and a
GP. Fourthly, we evaluated both HFrEF and HFpEF pa-
tients, although, for HFpEF ‘clear’ evidence-based treat-
ment is lacking. Nevertheless, HFpEF is part of the heart
failure spectrum, and has nearly as poor a prognosis as
HFrEF. Moreover, these patients suffer of symptoms,
notably fluid retention causing shortness of breath and
peripheral oedema. These symptoms can adequately
managed with diuretics. Physicians should realize that
symptom relieve is of utmost importance in these pa-
tients by titrating the dose of diuretics as optimally as
possible. Adjustments of diuretic dose to filling status is
really the ‘art’ of medicine. Even more can be done in
patients with HFpEF; blood pressure and comorbidities
should be adequately managed according to the ESC
guidelines 2012. Finally, the recommendation to GPs in
both trial arms to refer for echocardiography before the
training may increase awareness of HF diagnosis and
management and may dilute the effect of the
intervention.
We realize there are other options to improve the care
of patients with HF in general practice, such as a multi-
disciplinary approach, practice nurse-led disease man-
agement, or tele-health. Tele-health, providing daily-wise
data of body weight, blood pressure, pulse, and some-
times even much more biological data could also im-
prove the care of the complex patients with HF. Many
previous studies evaluated patients under the care of HF
outpatient clinics receiving multidisciplinary care, and
this resulted in prognostic beneficial effects [16]. Also
practice nurses in primary care could be helpful in the
care of patients with HF in the home setting. In the pri-
mary care setting in the Netherlands, disease-specific
care pathways have been developed for diabetes mellitus,
chronic obstructive pulmonary disease (COPD), and car-
diovascular risk management. In these programs, prac-
tice nurses play an important role. They receive a special
training to monitor these patients. These nurses, how-
ever, are not yet trained to care for HF, a disease with
multiple systemic effects, and high morbidity and mor-
tality. Training them in HF would also be an option to
upgrade the care of HF in the primary care setting.
Our study approach is focussed on a single interven-
tion that could improve care and would be easily imple-
mented if effective. We want to improve all aspects of
drug use in heart failure, also considering interaction,
contraindication, and adherence. We realize that our
strategy could gain by paying even more attention to
self-care of patients, and by facilitating cooperative care
of the cardiologist and HF nurse.
We realize that our intervention is relatively small, but
importantly, we focus on probably the most important
aspect of HF management, namely real adequate drug
use. The advantage of our approach is that it can easily
be implemented in everyday primary care.
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